Casens

Based in China, Casens is a molecular diagnostics company focused on developing advanced biotechnological solutions for healthcare. Their innovative products enhance diagnostic accuracy and therapeutic efficacy, contributing to improved patient care. Casens operates as Suzhou Guoke Xingan Medical Technology, founded in 2016 in Suzhou, China. The company specializes in molecular diagnostics and has not undergone any recent pivots or structural changes.

As of June 2025, Casens raised an undisclosed amount in SERIES A funding, indicating its position as an investment target in the biotechnology sector. Suzhou Guoke Xingan Medical Technology specializes in advanced biological science research and development, delivering innovative healthcare solutions designed to enhance quality of life. Their core products, aimed at healthcare providers, laboratories, and research institutions, include a range of medical technologies that apply biotechnological advancements to tackle various health challenges, particularly in diagnostics and therapy. The company serves a diverse clientele across multiple regions, including China, Southeast Asia, and Europe, while emphasizing scientific integrity and business ethics in its operations.

Suzhou Guoke Xingan Medical Technology generates revenue primarily through direct sales and partnerships with healthcare institutions and research facilities. Their transaction model is B2B, catering to clients who purchase products individually or in bulk for institutional use. Pricing plans are tailored for various customer segments, focusing on flagship products that utilize advanced biotechnological features, supported by long-term collaborations that contribute to ongoing product development and service offerings. In June 2025, Casens plans to utilize the funding raised in SERIES A to boost technological innovation and enhance market competitiveness.

They are focusing on the development of new products aimed at addressing evolving healthcare needs and expanding into new markets, specifically targeting regions outside of China, including Southeast Asia and Europe, by 2026. The funding will support these initiatives, ensuring the company remains at the forefront of innovation within the biotechnology field.